The week in pharma: action, reaction and insight – week to February 16, 2024
By Barbara Obstoj-Cardwell. Editor
M&A continued to feature in the news last week, as Gilead Sciences announced plans to acquire fellow USA-based CymaBay Therapeutics and its liver disease candidate seladelpar for around $4.3 billion. On a negative development, AN2 Therapeutics saw its market capitalization crash 74% after it revealed it is pausing enrollment of a Phase III study of epetraborole in lung cancer, Also of note, Brii Biosciences announced another research collaboration with VBI Vaccines in lung cancer. Sarepta Therapeutics announced that the US Food and Drug Administration (FDA) has accepted its application for an extended indication for its Duchenne muscular dystrophy drug Elevidys.
Gilead to buy CymaBay, lead liver disease asset seladelpar for $4.3B
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Biotechnology
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze